Cost analysis of hypertension management in an urban primary medical centre kuala lumpur

Azimatun Noor Aizuddin, M. N. Amrizal, T. Weng Kang, A. R. Rafidah, Y. Geok Hong, A. Adibah, Aniza Ismail, Sharifa Ezat Wan Puteh, Mohd Rizal Abdul Manaf

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hypertension is one of the commonest health problems in Malaysia and its cases are on a rise. In conjunction with the above statement, it is predictable that the cost of healthcare services will further increase in the future. Therefore, cost study is necessary to estimate the health related economic burden of hypertension in Malaysia. A cross sectional study was carried out to quantify the direct treatment cost of hypertension. Three hundred and ninety one hypertensive patients' data from Bandar Tasik Selatan Primary Medical Centre in year 2010 were collected and analysed. The direct treatment costs were calculated. The result showed that out of 391 hypertensive patients, 12.5% was diagnosed hypertensive without any co-morbidity, 25.3% with 1 co-morbidity dyslipidemia only; 4.3% with diabetes mellitus type 2 only; 0.5% with chronic kidney disease only and none with ischaemic heart disease. Patients with 2 co-morbidities (dyslipidemia and diabetes mellitus type 2) were 42.2%; with 3 co-morbidities (diabetes mellitus type 2, dyslipidemia and chronic kidney disease) was 4.3%. The mean cost of direct treatment of hypertension per visit/year was RM289.42 ±196.71 with the breakdown costs for each component were medicines 72.2%, salary 14.6%, laboratory tests 5.0%, administration 4.4% and radiology tests 3.8%. Dyslipidemia is by far the commonest co-morbidity among hypertensive patients. Direct costs of treating hypertension are mostly dependent on present of co-morbidity and numbers of drugs used. Thus, the annual budget could be calculated precisely in the future especially for drugs.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalMalaysian Journal of Public Health Medicine
Volume14
Issue number3
Publication statusPublished - 2014

Fingerprint

Dyslipidemias
Hypertension
Morbidity
Costs and Cost Analysis
Health Care Costs
Type 2 Diabetes Mellitus
Malaysia
Chronic Renal Insufficiency
Salaries and Fringe Benefits
Health
Budgets
Radiology
Pharmaceutical Preparations
Myocardial Ischemia
Cross-Sectional Studies
Economics

Keywords

  • Cost analysis
  • Hypertension
  • Primary medical centre

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cost analysis of hypertension management in an urban primary medical centre kuala lumpur. / Aizuddin, Azimatun Noor; Amrizal, M. N.; Weng Kang, T.; Rafidah, A. R.; Geok Hong, Y.; Adibah, A.; Ismail, Aniza; Wan Puteh, Sharifa Ezat; Abdul Manaf, Mohd Rizal.

In: Malaysian Journal of Public Health Medicine, Vol. 14, No. 3, 2014, p. 18-23.

Research output: Contribution to journalArticle

@article{4f36e00d70c34790ad39301d999ed840,
title = "Cost analysis of hypertension management in an urban primary medical centre kuala lumpur",
abstract = "Hypertension is one of the commonest health problems in Malaysia and its cases are on a rise. In conjunction with the above statement, it is predictable that the cost of healthcare services will further increase in the future. Therefore, cost study is necessary to estimate the health related economic burden of hypertension in Malaysia. A cross sectional study was carried out to quantify the direct treatment cost of hypertension. Three hundred and ninety one hypertensive patients' data from Bandar Tasik Selatan Primary Medical Centre in year 2010 were collected and analysed. The direct treatment costs were calculated. The result showed that out of 391 hypertensive patients, 12.5{\%} was diagnosed hypertensive without any co-morbidity, 25.3{\%} with 1 co-morbidity dyslipidemia only; 4.3{\%} with diabetes mellitus type 2 only; 0.5{\%} with chronic kidney disease only and none with ischaemic heart disease. Patients with 2 co-morbidities (dyslipidemia and diabetes mellitus type 2) were 42.2{\%}; with 3 co-morbidities (diabetes mellitus type 2, dyslipidemia and chronic kidney disease) was 4.3{\%}. The mean cost of direct treatment of hypertension per visit/year was RM289.42 ±196.71 with the breakdown costs for each component were medicines 72.2{\%}, salary 14.6{\%}, laboratory tests 5.0{\%}, administration 4.4{\%} and radiology tests 3.8{\%}. Dyslipidemia is by far the commonest co-morbidity among hypertensive patients. Direct costs of treating hypertension are mostly dependent on present of co-morbidity and numbers of drugs used. Thus, the annual budget could be calculated precisely in the future especially for drugs.",
keywords = "Cost analysis, Hypertension, Primary medical centre",
author = "Aizuddin, {Azimatun Noor} and Amrizal, {M. N.} and {Weng Kang}, T. and Rafidah, {A. R.} and {Geok Hong}, Y. and A. Adibah and Aniza Ismail and {Wan Puteh}, {Sharifa Ezat} and {Abdul Manaf}, {Mohd Rizal}",
year = "2014",
language = "English",
volume = "14",
pages = "18--23",
journal = "Malaysian Journal of Public Health Medicine",
issn = "1675-0306",
publisher = "Malaysian Public Health Physicians' Association",
number = "3",

}

TY - JOUR

T1 - Cost analysis of hypertension management in an urban primary medical centre kuala lumpur

AU - Aizuddin, Azimatun Noor

AU - Amrizal, M. N.

AU - Weng Kang, T.

AU - Rafidah, A. R.

AU - Geok Hong, Y.

AU - Adibah, A.

AU - Ismail, Aniza

AU - Wan Puteh, Sharifa Ezat

AU - Abdul Manaf, Mohd Rizal

PY - 2014

Y1 - 2014

N2 - Hypertension is one of the commonest health problems in Malaysia and its cases are on a rise. In conjunction with the above statement, it is predictable that the cost of healthcare services will further increase in the future. Therefore, cost study is necessary to estimate the health related economic burden of hypertension in Malaysia. A cross sectional study was carried out to quantify the direct treatment cost of hypertension. Three hundred and ninety one hypertensive patients' data from Bandar Tasik Selatan Primary Medical Centre in year 2010 were collected and analysed. The direct treatment costs were calculated. The result showed that out of 391 hypertensive patients, 12.5% was diagnosed hypertensive without any co-morbidity, 25.3% with 1 co-morbidity dyslipidemia only; 4.3% with diabetes mellitus type 2 only; 0.5% with chronic kidney disease only and none with ischaemic heart disease. Patients with 2 co-morbidities (dyslipidemia and diabetes mellitus type 2) were 42.2%; with 3 co-morbidities (diabetes mellitus type 2, dyslipidemia and chronic kidney disease) was 4.3%. The mean cost of direct treatment of hypertension per visit/year was RM289.42 ±196.71 with the breakdown costs for each component were medicines 72.2%, salary 14.6%, laboratory tests 5.0%, administration 4.4% and radiology tests 3.8%. Dyslipidemia is by far the commonest co-morbidity among hypertensive patients. Direct costs of treating hypertension are mostly dependent on present of co-morbidity and numbers of drugs used. Thus, the annual budget could be calculated precisely in the future especially for drugs.

AB - Hypertension is one of the commonest health problems in Malaysia and its cases are on a rise. In conjunction with the above statement, it is predictable that the cost of healthcare services will further increase in the future. Therefore, cost study is necessary to estimate the health related economic burden of hypertension in Malaysia. A cross sectional study was carried out to quantify the direct treatment cost of hypertension. Three hundred and ninety one hypertensive patients' data from Bandar Tasik Selatan Primary Medical Centre in year 2010 were collected and analysed. The direct treatment costs were calculated. The result showed that out of 391 hypertensive patients, 12.5% was diagnosed hypertensive without any co-morbidity, 25.3% with 1 co-morbidity dyslipidemia only; 4.3% with diabetes mellitus type 2 only; 0.5% with chronic kidney disease only and none with ischaemic heart disease. Patients with 2 co-morbidities (dyslipidemia and diabetes mellitus type 2) were 42.2%; with 3 co-morbidities (diabetes mellitus type 2, dyslipidemia and chronic kidney disease) was 4.3%. The mean cost of direct treatment of hypertension per visit/year was RM289.42 ±196.71 with the breakdown costs for each component were medicines 72.2%, salary 14.6%, laboratory tests 5.0%, administration 4.4% and radiology tests 3.8%. Dyslipidemia is by far the commonest co-morbidity among hypertensive patients. Direct costs of treating hypertension are mostly dependent on present of co-morbidity and numbers of drugs used. Thus, the annual budget could be calculated precisely in the future especially for drugs.

KW - Cost analysis

KW - Hypertension

KW - Primary medical centre

UR - http://www.scopus.com/inward/record.url?scp=84939807847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939807847&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84939807847

VL - 14

SP - 18

EP - 23

JO - Malaysian Journal of Public Health Medicine

JF - Malaysian Journal of Public Health Medicine

SN - 1675-0306

IS - 3

ER -